The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor
The data support targeting the AHR pathway as a dual tumor intrinsic and immune targeting therapeutic strategy for AML, particularly in combination with NK cellular therapy.
Authors
- Evan Lind (ORCID: https://orcid.org/0000-0001-7026-2012)
- Brian Druker (ORCID: https://orcid.org/0000-0001-8331-8206)
- Faith Burns
- Jennifer N. Saultz (ORCID: https://orcid.org/0000-0003-0024-9466)
- Nicola Long (ORCID: https://orcid.org/0000-0002-9010-8167)
- Andy Kaempf (ORCID: https://orcid.org/0000-0001-9425-6936)
- Bernhard Alber (ORCID: https://orcid.org/0000-0002-7601-4826)
- Jeffrey Tyner (ORCID: https://orcid.org/0000-0002-2133-0960)
- Daniel Bottomly (ORCID: https://orcid.org/0000-0001-7191-0990)
- Dan S. Kaufman (ORCID: https://orcid.org/0000-0002-2003-2494)
- Daniel Chandra
- Shannon K. McWeeney (ORCID: https://orcid.org/0000-0001-8333-6607)
- Yoko Kosaka (ORCID: https://orcid.org/0000-0003-4811-099X)
- Stephen E. Kurtz (ORCID: https://orcid.org/0000-0003-4762-389X)
- Kaelan Byrd (ORCID: https://orcid.org/0000-0002-0873-9956)
- Karen McGovern (ORCID: https://orcid.org/0000-0002-2578-3975)
- Lei Wang (ORCID: https://orcid.org/0000-0003-2553-0318)
- Guang Fan
- Marta Sánchez-Martín (ORCID: https://orcid.org/0000-0002-4821-058X)
Institutions
- Oregon Health & Science University (US)
- University of California San Diego (US)
- Sanford Consortium for Regenerative Medicine (US)
- International Organisation for Knowledge Economy and Enterprise Development (SE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1554166
- Primary Topic
- Toxic Organic Pollutants Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Oregon Health and Science University
- National Cancer Institute